TNF and inflammatory bowel disease: TNF‐α antagonists represented by adalimumab, infliximab, and golimumab effectively inhibit proinflammatory signaling by blocking the interaction between TNF‐α and its receptors, significantly reducing joint destruction and skin inflammation in diseases such as RA, psoriatic arthritis, and IBD [186, 213].